The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
The Real Drivers of This Market: AI, Semis...
S&P 500 Breaking Out Again: What This Means...
The Real Drivers of This Market: AI, Semis...
S&P 500 Breaking Out Again: What This Means...
Palantir joins list of 20 most valuable U.S....
The Real Drivers of This Market: AI, Semis...
S&P 500 Breaking Out Again: What This Means...
Chart Mania – 23 ATR Move in QQQ...
Microsoft’s Satya Nadella says job cuts have been...
FCC greenlights Paramount’s $8 billion merger with entertainment...

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Business

Elon Musk’s Neuralink raises $650 million in fresh capital

by admin June 4, 2025
June 4, 2025
Elon Musk’s Neuralink raises $650 million in fresh capital

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS

previous post
Stock Market News UK Update: FTSE 100 & 250 Rise
next post
Oil Prices Rebound After Trump’s Criticism of Powell

Related Posts

U.S. online stores put ‘out of stock’ signs...

June 12, 2025

Disney wins the 2024 box office as year-end...

January 16, 2025

IRS plans to pay 1 million taxpayers up...

December 25, 2024

White House accuses Powell of mismanaging Federal Reserve,...

July 11, 2025

Target rolls back DEI initiatives, the latest big...

January 26, 2025

Nvidia’s CEO did a Q&A with analysts. What...

March 24, 2025

UAW, U.S. dealers increase criticism of Stellantis CEO...

September 14, 2024

Wealthy investors find opportunities in stock market sell-offs

August 13, 2024

Dollar stores are struggling to win over bargain...

December 5, 2024

Procter & Gamble to cut 7,000 jobs as...

June 8, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • The Real Drivers of This Market: AI, Semis & Robotics
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio
    • The Real Drivers of This Market: AI, Semis & Robotics
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio
    • Palantir joins list of 20 most valuable U.S. companies, with stock more than doubling in 2025

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

      June 4, 2025
    • 5

      Donald Trump’s imaginary and frightening world

      September 23, 2024

    Categories

    • Business (756)
    • Economy (975)
    • Politics (873)
    • Stocks (924)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.